Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 4;9(6):598.
doi: 10.3390/vaccines9060598.

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom

Michele A Kohli  1 , Michael Maschio  1 , Joaquin F Mould-Quevedo  2 , Mansoor Ashraf  3 , Michael F Drummond  4 , Milton C Weinstein  5
Affiliations

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom

Michele A Kohli et al. Vaccines (Basel). .

Abstract

Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with a quadrivalent cell-based vaccine (QIVc) compared to returning to an at-risk only policy after the pandemic resolves.

Methods: A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the clinical and economic impact of vaccination across 10 influenza seasons. The base case effectiveness of QIVc was 63.9% and the list price was GBP 9.94.

Results: Vaccinating 50% of all 50- to 64-year-olds with QIVc reduced the average annual number of clinical infections (-682,000), hospitalizations (-5800) and deaths (-740) in the UK. The base case incremental cost per quality-adjusted life-year gained (ICER) of all compared to at-risk only was GBP6000 (NHS perspective). When the cost of lost productivity was considered, vaccinating all 50- to 64-year-olds with QIVc became cost-saving.

Conclusion: Vaccinating all 50- to 64-year-olds with QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons.

Keywords: cost-effectiveness; economic modeling; influenza vaccine.

PubMed Disclaimer

Conflict of interest statement

M.A.K. is a shareholder in Quadrant Health Economics Inc. Quadrant Health Economics Inc. was contracted by Seqirus USA Inc. to conduct this study. M.M., M.C.W. and M.F.D. are consultants at Quadrant Health Economics Inc. M.A. and J.F.M.-Q. are employed by Seqirus and shareholders of CSL Limited.

Figures

Figure 1
Figure 1
Tornado diagram: impact of the deterministic sensitivity analyses on the incremental cost per quality-adjusted life-year (NHS cost perspective) associated with vaccinating 50% of low risk individuals ages 50 to 64 years old.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ramsay M., editor. Immunisation against Infectious Disease. Public Health England; London, UK: 2018. [(accessed on 16 December 2020)]. Chapter 19 Influenza. Available online: https://www.gov.uk/government/collections/immunisation-against-infectiou....
    1. Joint Committee on Vaccination and Immunisation (JCVI) Scientific Secretariat JCVI Statement on the Annual Influenza Vaccination Programme–Extension of the Programme to Children. 25 July 2012. [(accessed on 10 December 2018)]; Available online: www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisa....
    1. Baguelin M., Camacho A., Flasche S., Edmunds W.J. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: A cost-effectiveness study. BMC Med. 2015;13:236. doi: 10.1186/s12916-015-0452-y. - DOI - PMC - PubMed
    1. National Health Service The National Flu Immunisation Programme 2020 to 2021-Update (Letter: 5 August 2020) [(accessed on 16 December 2020)]; Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploa....
    1. Thorrington D., van Leeuwen E., Ramsay M., Pebody R., Baguelin M. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly. Vaccine. 2019;37:2051–2056. doi: 10.1016/j.vaccine.2019.03.002. - DOI - PubMed